The best offense is a proactive defense
SureSkin Silver Hydrocolloid dressings combine the antibacterial effectiveness of silver with the proven healing efficacy of hydrocolloid technology
SureSkin Silver hydrocolloid dressings were designed to combine the proven efficacy of Euromed’s patented hydrocolloid adhesive technology with the well-established infection-fighting antibacterial effectiveness of ionic silver.
SureSkin Silver dressings can help to manage high risk patient populations such as the elderly, the physically and nutritionally debilitated, the immune suppressed, and those with co-morbidities like congestive heart failure, peripheral vascular disease, and diabetes. Many of these patients develop chronic wounds such as pressure ulcers, leg ulcers and diabetic foot ulcers.
What is different about SureSkin Silver dressings is that they are effective without the need to dump large amounts of silver into the wound bed. The activity of the silver ions in this dressing uniquely confine their attack to the bacteria absorbed into the gel mass that forms over the wound bed. As a result, there is little risk of staining or of the skin turning color and less potential for resistance to develop.
These dressings offer an effective alternative for helping health care professionals in their fight to reduce wound infection rates, and in particular, wound infections caused by antibiotic resistant organisms.
Using SureSkin Silver dressings on patients at high risk for possible wound infection could help to significantly reduce the rising cost incurred in managing these challenging clinical problems.
|
 |
  
|
An estimated 2.5 million patients are treated each year in US acute care facilities for pressure ulcers 1
The net cost is a staggering $12.9 Billion 2
60,000 patients die each year of pressure ulcer complications 2
Additional average charges for a hospital stay for pressure ulcers can cost $40,381 1
|
1. Lyder CH Pressure Ulcer prevention and management. JAMA. 2003; 389(2):223-226.
2. Reddy M, et al.preventing pressure ulcers: A systemic review, JAMA, 2006; 296(6):974-984.
US Patents; 6309500, 6143798, 59938694, 5571080, 5704905, 6592888
Other International patents apply. Additional patents pending.
|
